Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Preclinical analysis of human mesenchymal stem cells: tumor tropism and therapeutic efficiency of local HSV-TK suicide gene therapy in glioblastoma.

Dührsen L, Hartfuß S, Hirsch D, Geiger S, Maire CL, Sedlacik J, Guenther C, Westphal M, Lamszus K, Hermann FG, Schmidt NO.

Oncotarget. 2019 Oct 22;10(58):6049-6061. doi: 10.18632/oncotarget.27071. eCollection 2019 Oct 22.

2.

Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.

Bockmayr M, Klauschen F, Maire CL, Rutkowski S, Westphal M, Lamszus K, Schüller U, Mohme M.

Cancer Immunol Res. 2019 Sep;7(9):1401-1411. doi: 10.1158/2326-6066.CIR-18-0939. Epub 2019 Jul 2.

PMID:
31266783
3.

Imaging flow cytometry facilitates multiparametric characterization of extracellular vesicles in malignant brain tumours.

Ricklefs FL, Maire CL, Reimer R, Dührsen L, Kolbe K, Holz M, Schneider E, Rissiek A, Babayan A, Hille C, Pantel K, Krasemann S, Glatzel M, Heiland DH, Flitsch J, Martens T, Schmidt NO, Peine S, Breakefield XO, Lawler S, Chiocca EA, Fehse B, Giebel B, Görgens A, Westphal M, Lamszus K.

J Extracell Vesicles. 2019 Mar 21;8(1):1588555. doi: 10.1080/20013078.2019.1588555. eCollection 2019.

4.

The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects.

Kathagen-Buhmann A, Maire CL, Weller J, Schulte A, Matschke J, Holz M, Ligon KL, Glatzel M, Westphal M, Lamszus K.

Neuro Oncol. 2018 Nov 12;20(12):1594-1605. doi: 10.1093/neuonc/noy117.

5.

Immunophenotyping of Newly Diagnosed and Recurrent Glioblastoma Defines Distinct Immune Exhaustion Profiles in Peripheral and Tumor-infiltrating Lymphocytes.

Mohme M, Schliffke S, Maire CL, Rünger A, Glau L, Mende KC, Matschke J, Gehbauer C, Akyüz N, Zapf S, Holz M, Schaper M, Martens T, Schmidt NO, Peine S, Westphal M, Binder M, Tolosa E, Lamszus K.

Clin Cancer Res. 2018 Sep 1;24(17):4187-4200. doi: 10.1158/1078-0432.CCR-17-2617. Epub 2018 Feb 14.

6.

High grade serous ovarian carcinomas originate in the fallopian tube.

Labidi-Galy SI, Papp E, Hallberg D, Niknafs N, Adleff V, Noe M, Bhattacharya R, Novak M, Jones S, Phallen J, Hruban CA, Hirsch MS, Lin DI, Schwartz L, Maire CL, Tille JC, Bowden M, Ayhan A, Wood LD, Scharpf RB, Kurman R, Wang TL, Shih IM, Karchin R, Drapkin R, Velculescu VE.

Nat Commun. 2017 Oct 23;8(1):1093. doi: 10.1038/s41467-017-00962-1.

7.

EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise.

Westphal M, Maire CL, Lamszus K.

CNS Drugs. 2017 Sep;31(9):723-735. doi: 10.1007/s40263-017-0456-6. Review.

8.

Circulating Tumour Cell Release after Cement Augmentation of Vertebral Metastases.

Mohme M, Riethdorf S, Dreimann M, Werner S, Maire CL, Joosse SA, Bludau F, Mueller V, Neves RPL, Stoecklein NH, Lamszus K, Westphal M, Pantel K, Wikman H, Eicker SO.

Sci Rep. 2017 Aug 3;7(1):7196. doi: 10.1038/s41598-017-07649-z.

9.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2017 Jun 13;19(11):2410-2412. doi: 10.1016/j.celrep.2017.05.039. No abstract available.

10.

Optical Barcoding for Single-Clone Tracking to Study Tumor Heterogeneity.

Mohme M, Maire CL, Riecken K, Zapf S, Aranyossy T, Westphal M, Lamszus K, Fehse B.

Mol Ther. 2017 Mar 1;25(3):621-633. doi: 10.1016/j.ymthe.2016.12.014. Epub 2017 Jan 18.

11.

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.

Stevens MM, Maire CL, Chou N, Murakami MA, Knoff DS, Kikuchi Y, Kimmerling RJ, Liu H, Haidar S, Calistri NL, Cermak N, Olcum S, Cordero NA, Idbaih A, Wen PY, Weinstock DM, Ligon KL, Manalis SR.

Nat Biotechnol. 2016 Nov;34(11):1161-1167. doi: 10.1038/nbt.3697. Epub 2016 Oct 10.

12.

Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-β Pathway.

Singh SK, Fiorelli R, Kupp R, Rajan S, Szeto E, Lo Cascio C, Maire CL, Sun Y, Alberta JA, Eschbacher JM, Ligon KL, Berens ME, Sanai N, Mehta S.

Cell Rep. 2016 Jul 26;16(4):950-966. doi: 10.1016/j.celrep.2016.06.045. Epub 2016 Jul 7. Erratum in: Cell Rep. 2017 Jun 13;19(11):2410-2412.

13.

Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype.

Bergthold G, Bandopadhayay P, Hoshida Y, Ramkissoon S, Ramkissoon L, Rich B, Maire CL, Paolella BR, Schumacher SE, Tabak B, Ferrer-Luna R, Ozek M, Sav A, Santagata S, Wen PY, Goumnerova LC, Ligon AH, Stiles C, Segal R, Golub T, Grill J, Ligon KL, Chan JA, Kieran MW, Beroukhim R.

Neuro Oncol. 2015 Nov;17(11):1486-96. doi: 10.1093/neuonc/nov045. Epub 2015 Mar 29.

14.

Intermediate DNA methylation is a conserved signature of genome regulation.

Elliott G, Hong C, Xing X, Zhou X, Li D, Coarfa C, Bell RJ, Maire CL, Ligon KL, Sigaroudinia M, Gascard P, Tlsty TD, Harris RA, Schalkwyk LC, Bilenky M, Mill J, Farnham PJ, Kellis M, Marra MA, Milosavljevic A, Hirst M, Stormo GD, Wang T, Costello JF.

Nat Commun. 2015 Feb 18;6:6363. doi: 10.1038/ncomms7363.

15.

Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.

Green AL, Ramkissoon SH, McCauley D, Jones K, Perry JA, Hsu JH, Ramkissoon LA, Maire CL, Hubbell-Engler B, Knoff DS, Shacham S, Ligon KL, Kung AL.

Neuro Oncol. 2015 May;17(5):697-707. doi: 10.1093/neuonc/nou303. Epub 2014 Nov 2.

16.

Molecular pathologic diagnosis of epidermal growth factor receptor.

Maire CL, Ligon KL.

Neuro Oncol. 2014 Oct;16 Suppl 8:viii1-6. doi: 10.1093/neuonc/nou294. Review.

17.

Prominin-1 (CD133) defines both stem and non-stem cell populations in CNS development and gliomas.

Holmberg Olausson K, Maire CL, Haidar S, Ling J, Learner E, Nistér M, Ligon KL.

PLoS One. 2014 Sep 3;9(9):e106694. doi: 10.1371/journal.pone.0106694. eCollection 2014.

18.

EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.

Francis JM, Zhang CZ, Maire CL, Jung J, Manzo VE, Adalsteinsson VA, Homer H, Haidar S, Blumenstiel B, Pedamallu CS, Ligon AH, Love JC, Meyerson M, Ligon KL.

Cancer Discov. 2014 Aug;4(8):956-71. doi: 10.1158/2159-8290.CD-13-0879. Epub 2014 Jun 3.

19.

Pten loss in Olig2 expressing neural progenitor cells and oligodendrocytes leads to interneuron dysplasia and leukodystrophy.

Maire CL, Ramkissoon S, Hayashi M, Haidar S, Ramkissoon L, DiTomaso E, Ligon KL.

Stem Cells. 2014 Jan;32(1):313-26. doi: 10.1002/stem.1590.

20.

Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods.

Stevens M, Cheng JB, Li D, Xie M, Hong C, Maire CL, Ligon KL, Hirst M, Marra MA, Costello JF, Wang T.

Genome Res. 2013 Sep;23(9):1541-53. doi: 10.1101/gr.152231.112. Epub 2013 Jun 26.

21.

Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm.

Zhang B, Zhou Y, Lin N, Lowdon RF, Hong C, Nagarajan RP, Cheng JB, Li D, Stevens M, Lee HJ, Xing X, Zhou J, Sundaram V, Elliott G, Gu J, Shi T, Gascard P, Sigaroudinia M, Tlsty TD, Kadlecek T, Weiss A, O'Geen H, Farnham PJ, Maire CL, Ligon KL, Madden PA, Tam A, Moore R, Hirst M, Marra MA, Zhang B, Costello JF, Wang T.

Genome Res. 2013 Sep;23(9):1522-40. doi: 10.1101/gr.156539.113. Epub 2013 Jun 26.

22.

Ascl1/Mash1 promotes brain oligodendrogenesis during myelination and remyelination.

Nakatani H, Martin E, Hassani H, Clavairoly A, Maire CL, Viadieu A, Kerninon C, Delmasure A, Frah M, Weber M, Nakafuku M, Zalc B, Thomas JL, Guillemot F, Nait-Oumesmar B, Parras C.

J Neurosci. 2013 Jun 5;33(23):9752-9768. doi: 10.1523/JNEUROSCI.0805-13.2013.

23.

DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape.

Xie M, Hong C, Zhang B, Lowdon RF, Xing X, Li D, Zhou X, Lee HJ, Maire CL, Ligon KL, Gascard P, Sigaroudinia M, Tlsty TD, Kadlecek T, Weiss A, O'Geen H, Farnham PJ, Madden PA, Mungall AJ, Tam A, Kamoh B, Cho S, Moore R, Hirst M, Marra MA, Costello JF, Wang T.

Nat Genet. 2013 Jul;45(7):836-41. doi: 10.1038/ng.2649. Epub 2013 May 26.

24.

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma.

Mehta S, Huillard E, Kesari S, Maire CL, Golebiowski D, Harrington EP, Alberta JA, Kane MF, Theisen M, Ligon KL, Rowitch DH, Stiles CD.

Cancer Cell. 2011 Mar 8;19(3):359-71. doi: 10.1016/j.ccr.2011.01.035.

25.

Glioma models: new GEMMs add "class" with genomic and expression correlations.

Maire CL, Ligon KL.

Cancer Cell. 2011 Mar 8;19(3):295-7. doi: 10.1016/j.ccr.2011.02.018.

26.

Gain-of-function of Olig transcription factors enhances oligodendrogenesis and myelination.

Maire CL, Wegener A, Kerninon C, Nait Oumesmar B.

Stem Cells. 2010 Sep;28(9):1611-22. doi: 10.1002/stem.480.

27.

CRX is a diagnostic marker of retinal and pineal lineage tumors.

Santagata S, Maire CL, Idbaih A, Geffers L, Correll M, Holton K, Quackenbush J, Ligon KL.

PLoS One. 2009 Nov 20;4(11):e7932. doi: 10.1371/journal.pone.0007932.

28.

Directing human neural stem/precursor cells into oligodendrocytes by overexpression of Olig2 transcription factor.

Maire CL, Buchet D, Kerninon C, Deboux C, Baron-Van Evercooren A, Nait-Oumesmar B.

J Neurosci Res. 2009 Nov 15;87(15):3438-46. doi: 10.1002/jnr.22194.

PMID:
19739249
29.

Les convulsionnaires à Paris au XVIII siècle.

Maire CL.

Penelope. 1983;(8):29-34. French. No abstract available.

PMID:
11632673

Supplemental Content

Loading ...
Support Center